{"id":"naft-500","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL3656202","moleculeType":"Small molecule","molecularWeight":"369.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naftifine is a benzylamine antifungal agent that inhibits fungal sterol synthesis; NAFT-500 appears to be a formulation or derivative variant being developed for topical dermatological use. The phase 3 development suggests evaluation in a specific skin condition, likely fungal infection or inflammatory dermatosis where naftifine's antifungal and anti-inflammatory properties are therapeutically relevant.","oneSentence":"NAFT-500 is a naftifine derivative designed to modulate skin barrier function and reduce inflammation in dermatological conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:29.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Fungal skin infection (specific indication under phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT01712360","phase":"PHASE4","title":"Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2012-10","conditions":"Tinea Pedis, Tinea Cruris","enrollment":56},{"nctId":"NCT00750139","phase":"PHASE3","title":"Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2008-08","conditions":"Tinea Pedis, Athlete's Foot","enrollment":707},{"nctId":"NCT00750152","phase":"PHASE3","title":"Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2008-09","conditions":"Tinea Cruris, Jock Itch","enrollment":334}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NAFT-500","genericName":"NAFT-500","companyName":"Merz North America, Inc.","companyId":"merz-north-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NAFT-500 is a naftifine derivative designed to modulate skin barrier function and reduce inflammation in dermatological conditions. Used for Fungal skin infection (specific indication under phase 3 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}